A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)
Phase 3
Completed
- Conditions
- Restless Legs Syndrome
- Registration Number
- NCT00225862
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
A 12-week clinical research study to evaluate the tolerability, efficacy and safety of ropinirole compared to placebo(an inactive sugar pill) in the treatment of patients with RLS in the United States.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Average proportion of nights a subject has successfully treated his/her RLS symptoms after taking study medication for that night out of total number of nights dosed during the Double-Blind Phase. 12 Weeks
- Secondary Outcome Measures
Name Time Method Quality and satisfaction with sleep, severity of symptoms 2 hours post dosing with study medication. 12 Weeks
Trial Locations
- Locations (1)
GSK Investigational Site
🇺🇸Wenatchee, Washington, United States